Photo by Welshsk via Wikimedia Commons The use of glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used to manage type 2 diabetes mellitus (T2DM) and obesity, appears to increase the risk of nonscarring hair loss (NSHL). These findings were published online ahead of print in the Journal of the American Academy of Dermatology . In the paper, the authors note that emerging reports suggest potential dermatologic adverse effects associated with GLP-1RA use, particular

Photo by: Thirunavukkarasye-Raveendran via Wikimedia commons Findings from a large case-control study support a link between alopecia...

Dr. Kyle Lauck Comorbidities play a role in the sexual dysfunction linked to use of 5-alpha-reductase inhibitors prescribed for...

Findings from a new study suggest that taking oral contraceptives could be linked to frontal fibrosing alopecia (FFA). The study,...

A recent study found a link between alopecia areata (AA) and cochlear dysfunction leading to hearing loss. The authors of the paper,...

Researchers from QIMR Berghofer have uncovered new evidence that explores the trend that people with hair loss can be more susceptible to...

A new study from Korea has determined that children of mothers with alopecia areata (AA) appear to be at higher risk of developing...

The Chronicle of Skin & Allergy, in partnership with the Dermatology Industry Taskforce on Inclusion, Diversity and Equity (DiTiDE),...